SCHEMBL4650285

SCHEMBL4650285

O=C(OCC1C2CN(Cc3ccccc3)CC12)C1Cc2ccccc2CN1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.43
MEN1 O00255 2/20 0.43
S1PR5 Q9H228 2/20 0.38
S1PR1 P21453 1/20 0.38
BCHE P06276 4/20 0.37
ACHE P22303 4/20 0.37
MAOB P27338 2/20 0.37
FUCA1 P04066 2/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
OPRM1 P35372 2/20 0.36
OPRD1 P41143 2/20 0.36
OPRK1 P41145 2/20 0.36
SIGMAR1 Q99720 1/20 0.36
BLM P54132 1/20 0.36
ARG1 P05089 1/20 0.36
ARG2 P78540 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4913374 0.83 KMT2A (0.56) KMT2AMEN1PRMT5WDR77OPRM1
SCHEMBL8235210 0.77 KMT2A (0.53) KMT2AMEN1OPRM1OPRD1OPRK1
SCHEMBL7677497 0.77 KMT2A (0.53) KMT2AMEN1OPRM1OPRD1OPRK1
SCHEMBL27627519 0.77 KMT2A (0.53) KMT2AMEN1OPRM1OPRD1OPRK1
Hydrochloric Acid SCHEMBL10755389 0.76 MEN1 (0.55) KMT2AMEN1OPRM1OPRD1OPRK1
SCHEMBL4925547 0.74 NR1D1 (0.40) BCHEACHESIGMAR1
SCHEMBL13981210 0.72 ATM (0.50) KMT2AMEN1
SCHEMBL3319088 0.72 KDM4E (0.57) KMT2AMEN1OPRM1OPRD1OPRK1
SCHEMBL7744084 0.72 KDM4E (0.57) KMT2AMEN1OPRM1OPRD1OPRK1
SCHEMBL31669038 0.72 KDM4E (0.57) KMT2AMEN1OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255188-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-10-16 US claimed
US-20080255188-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-10-16 US disclosed
EP-1904495-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP disclosed
WO-2007007281-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255188-A1 Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 KMT2A 3036/4885MEN1 1581/4885S1PR5 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.